Flecainide
- Generic Name
- Flecainide
- Brand Names
- Tambocor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F6N2O3
- CAS Number
- 54143-55-4
- Unique Ingredient Identifier
- K94FTS1806
- Background
Flecainide is a Class I anti-arrhythmic agent like encainide and propafenone. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
...
- Indication
In New Zealand and America, flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmias. In the United States, it is also indicated to prevent paroxysmal atrial fibrillation and flutter.
- Associated Conditions
- Atrial Fibrillation, Ventricular Tachycardia (VT), Severe Atrioventricular nodal reentrant tachycardia, Severe Paroxysmal atrial fibrillation, Severe Paroxysmal supraventricular tachycardia, Severe Supraventricular Tachycardias, Severe Sustained ventricular tachycardia, Severe ventricular arrhythmias
- Associated Therapies
- -
N-of-1 in ATS and MEPPC
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 10
- Registration Number
- NCT06205550
Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Population Health Research Institute
- Registration Number
- NCT06142604
Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05631730
- Locations
- 🇳🇴
Oslo University Hospital Rikshospitalet, Oslo, Norway
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 186
- Registration Number
- NCT05213104
- Locations
- 🇫🇷
Hopital Pitié Salpetrière, Paris, IDF, France
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
- Conditions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Tampere University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04837261
- Locations
- 🇫🇮
Hämeenlinna Central Hospital, Hämeenlinna, Kanta-Häme, Finland
🇫🇮Sakunta Central Hospital, Pori, Satakunta, Finland
🇫🇮Central Finland Central Hospital, Jyväskylä, Central Finland, Finland
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Keimyung University Dongsan Medical Center
- Target Recruit Count
- 104
- Registration Number
- NCT03587558
- Locations
- 🇰🇷
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Seoul Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Cardiovascular Hospital, Seoul, Korea, Republic of
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- InCarda Therapeutics, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03539302
- Locations
- 🇧🇪
Imelda, Bonheiden, Belgium
🇳🇱OLVG, Amsterdam, Netherlands
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents
- Conditions
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- David Filgueiras-Rama
- Target Recruit Count
- 50
- Registration Number
- NCT03005366
- Locations
- 🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Madrid/Madrid, Spain
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 162
- Registration Number
- NCT02347111
- Locations
- 🇺🇸
Jesse Brown VA Medical Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT02294955
- Locations
- 🇸🇪
Carina Blomström Lundqvist, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.